Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

Must have received: systemic therapy — HCC

HCC has progressed on at least 1, but no more than 2, prior systemic treatment regimens

Cannot have received: systemic drug therapy

Receipt of >2 prior systemic drug therapies for HCC

Cannot have received: systemic cancer therapy

Exception: within 14 days prior to the Baseline Visit or concurrently during the trial

Receipt of systemic cancer therapy, immunomodulatory drug therapy, immunosuppressive therapy, or corticosteroids > 20 mg/day prednisone or equivalent within 14 days prior to the Baseline Visit or concurrently during the trial

Cannot have received: locoregional treatment

Exception: within 4 weeks prior to the Baseline Visit

Locoregional treatment within 4 weeks prior to the Baseline Visit

Cannot have received: major surgery or radiation therapy

Exception: within 4 weeks prior to the Baseline Visit

Major surgery or radiation therapy within 4 weeks prior to the Baseline Visit

Cannot have received: investigational agent

Exception: within 4 weeks prior to the Baseline Visit

Use of any investigational agent within 4 weeks prior to the Baseline Visit